- CEO
- Lie Ming Ding
- Full Time Employees
- 1,785
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 355, Xingzhong Road Hangzhou ZH China 311100
- IPO Date
- Nov 9, 2016
- Business
- Betta Pharmaceuticals Co., Ltd. (300558.SZ) is a China-based biopharmaceutical company primarily engaged in the research, development, production and commercialization of innovative oncology drugs targeting malignant tumors, including non-small cell lung cancer (NSCLC), renal cell carcinoma and other solid tumors. Founded in 2003 and headquartered in Hangzhou, Zhejiang Province, the company integrates end-to-end operations across R&D, manufacturing and sales, with over 1,700 employees and R&D centers in Hangzhou and Beijing; it listed on the Shenzhen Stock Exchange in November 2016. Betta offers a portfolio of marketed products including Icotinib hydrochloride (Conmana®), China's first domestically developed small molecule EGFR tyrosine kinase inhibitor (TKI) approved in 2011 for first-line treatment of EGFR-mutated locally advanced or metastatic NSCLC; Ensartinib hydrochloride (Ensacove®), a next-generation ALK inhibitor approved in China in 2020 for ALK-positive advanced NSCLC and receiving U.S. FDA approval in December 2024 as the first globally marketed small-molecule lung cancer targeted drug led by a Chinese firm; Bevacizumab biosimilar (MIL60), approved in November 2021 for metastatic colorectal cancer and advanced NSCLC with additional indications added in 2022; Befotertinib (Surmana®), a third-generation EGFR-TKI approved in May 2023 for T790M-mutated NSCLC post-first-generation TKI resistance; and Vorolanib (CM082), a multi-target kinase inhibitor approved in June 2023 in combination with everolimus for advanced renal cell carcinoma progressing after TKI therapy. The company's pipeline encompasses over 20 programs in clinical stages, such as bispecific antibody MCLA-129 targeting EGFR/c-Met for advanced solid tumors, PD-L1 inhibitor BPI-371153, HIF-2α inhibitor BPI-452080, TEAD inhibitor BPI-460372 and EGFR degrader CFT8919, alongside investigational candidates like EYP-1901 for ophthalmic conditions using vorolanib with Durasert delivery technology. Betta primarily serves oncologists, hospitals and patients in China, with expanding global ambitions highlighted by Ensartinib's U.S. approval, and maintains strategic partnerships including collaborations with C4 Therapeutics in May 2023, Agenus for PD-1/CTLA-4 antibodies since 2020, Xcovery as a subsidiary for ALK inhibitors since 2014-2017, and prior investments in Mabworks, Anew Pharma, Repugene and others to bolster biologics and targeted therapies. Recent developments underscore Betta's R&D momentum, with R&D spending averaging over 40% of revenues and initiatives like the Betta Dreamworks incubator fostering external innovation.